CN1299707C - Yinhuang oral liquor and its producing process - Google Patents
Yinhuang oral liquor and its producing process Download PDFInfo
- Publication number
- CN1299707C CN1299707C CN 200410080022 CN200410080022A CN1299707C CN 1299707 C CN1299707 C CN 1299707C CN 200410080022 CN200410080022 CN 200410080022 CN 200410080022 A CN200410080022 A CN 200410080022A CN 1299707 C CN1299707 C CN 1299707C
- Authority
- CN
- China
- Prior art keywords
- extract
- concentration
- add
- stabilizing agent
- radix scutellariae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention discloses a Yinhuang oral liquid and a preparation method thereof. The Yinhuang oral liquid is composed of 6 to 24 mg/ml of honeysuckle extract (measured by chlorogenic acid), 12 to 48 mg/ml of scutellaria root extract (measured by scutellaria root), 18 to 72 mg/ml of stabilizing agent and 0.1 to 1 mg/ml of pH stabilizing agent. The medicine has stable quality, high medicine effect and good curative effect.
Description
Technical field
The present invention relates to a kind of Chinese medicine oral liquid and production technology thereof, particularly a kind of YINHUANG KOUFUYE and production technology thereof.
Background technology
YINHUANG KOUFUYE is our factory carries out modified form on the basis of YINHUANG PIAN a kind, and its main component is Flos Lonicerae extract and Radix Scutellariae extract, and main effect is heat-clearing and toxic substances removing, anti-inflammation.Be used for upper respiratory tract infection such as acute tonsillitis, pharyngitis, and the cough that common cold initial stage and flu cause is had curative effect preferably, also have preventing cold, hoarseness, cough, aphtha of the mouth and tongue, hepatitis, the effect of parotitis dysentery.This medicine has been documented in one one 2000 editions the 580th page of the Pharmacopoeia of the People's Republic of China, its production technology is: extracting honeysuckle extract, Radix Scutellariae extract are dissolved in water respectively, Radix Scutellariae extract is regulated pH value to 8 at the sodium hydroxide solution with 8%, filter with Flos Lonicerae extract solution and merge, regulate pH value to 7.2 with 8% sodium hydroxide solution, boiled 1 hour, and filtered, the adding simple syrup is an amount of, add water to nearly full dose, stir evenly, regulate pH value to 7.2, add water to 1000ml with 8% sodium hydroxide solution, filter, embedding, sterilization, promptly.This product from our factory since first tissue in 1998 is produced and is put on market since determined curative effect, effect rapidly, taking convenience, characteristics such as have no side effect are welcome by extensive patients, product just reaches each province and city and vast rural area.But this product remains in following deficiency: (1), the pH value along with the prolongation medicinal liquid of standing time in storage process reduce gradually, medicinal liquid color, clarity are changed influence drug quality, especially the pH value decline of medicinal liquid sterilization back is more, descends more than 1.0 sometimes.(2), contain multiple compositions such as baicalin, baicalin in the Radix Scutellariae extract, wherein Radix Scutellariae have antiinflammatory, antiallergic action, antibacterial action, function of gallbladder promoting, diuresis, anti-cholesterol effect, be widely used in sick clinical treatment such as infectious hepatitis, nephritis, pyelonephritis, but because baicalin is water-soluble hardly, do not contain carboxyl yet and be insoluble to aqueous alkali, thereby indissoluble separates, and is taken as contaminant filter and goes out, and influences the curative effect of medicine.Simultaneously baicalin contains that dissolubility increases in the carboxyl diluted alkaline, but its stability is bad, separate out along with the variation of solution pH value can precipitate from solution between the storage life simultaneously, or hydrolysis generates the water-soluble hardly generation of baicalin and precipitates the clarity that influences medicine.(3), chlorogenic acid is the caffeic acid quinate, thereby can also can be, thereby the pH value of drug solution had relatively high expectations by alkali catalyzed hydrolysis by acid, medicinal liquid PH changes back hydrolysis easily, and influences the curative effect of medicine.
Summary of the invention
The purpose of this invention is to provide a kind of being used for the treatment of and upper respiratory tract infection such as prophylaxis of acute tonsillitis, pharyngitis, the oral liquid of the cough that common cold initial stage and flu cause, this drug quality is more stable, and drug effect is higher, better efficacy.Another object of the present invention provides a kind of technology of production YINHUANG KOUFUYE.
For achieving the above object, we have adopted following technical scheme:
YINHUANG KOUFUYE provided by the present invention mainly transfers PH to 7-8 to form by Flos Lonicerae extract 6-24mg (in chlorogenic acid)/ml, Radix Scutellariae extract 12-48mg (in baicalin)/ml, stabilizing agent 18-72mg/ml, PH stabilizing agent 0.1-1mg/ml, sodium hydroxide; Described oral liquid solvent is a water.
Wherein the concentration of Flos Lonicerae extract is preferably 12mg (in chlorogenic acid)/ml, and Radix Scutellariae extract is preferably 24mg (in baicalin)/ml; But described stabilizing agent pluronic F-68, β-CD, glucose or PVP etc. are preferably HP-β-CD, and the concentration of HP-β-CD is preferably 24-38mg/ml between 18-72mg/ml; Described PH stabilizing agent can be sodium citrate, citric acid, phosphate, sulfate, is preferably sodium citrate, and the concentration of sodium citrate is 0.1-1mg/ml, is preferably 0.1mg/ml-0.5mg/ml.
The preparation technology of oral liquid is as mentioned above:
It is 6-24mg (in chlorogenic acid)/ml that the extracting honeysuckle extract makes its concentration in finished product in right amount, it is that 12-48mg (in baicalin)/ml is dissolved in water respectively that Radix Scutellariae extract makes its concentration in finished product in right amount, Radix Scutellariae extract is regulated pH value to 8 at the sodium hydroxide solution with 8%, filter with Flos Lonicerae extract solution and merge, regulate pH value to 7.2 with 8% sodium hydroxide solution, boiled 1 hour, filter, it is 18-72mg/ml that the adding stabilizing agent makes its concentration in finished product, stirs dissolving, it is an amount of to add simple syrup, add water to nearly full dose, stir evenly, add an amount of PH stabilizing agent, the concentration that makes the PH stabilizing agent is 0.1mg/ml-1mg/ml, add water to 1000ml, filter embedding, sterilization, promptly.
The best preparation technology of oral liquid is as mentioned above:
It is 12mg (in chlorogenic acid)/ml that the extracting honeysuckle extract makes its concentration in finished product in right amount, it is that 24mg (in baicalin)/ml is dissolved in water respectively that Radix Scutellariae extract makes its concentration in finished product in right amount, Radix Scutellariae extract is regulated pH value to 8 at the sodium hydroxide solution with 8%, filter with Flos Lonicerae extract solution and merge, regulate pH value to 7.2 with 8% sodium hydroxide solution, boiled 1 hour, filter, it is 24-38mg/ml that adding stabilizing agent HP-β-CD makes its concentration in finished product, stirs dissolving, it is an amount of to add simple syrup, add water to nearly full dose, stir evenly, add an amount of sodium citrate, the concentration that makes sodium citrate is 0.1mg/ml-0.5mg/ml, add water to 1000ml, filter embedding, sterilization, promptly.
Medicine of the present invention is formed and the production technology novelty, and is practical, especially adds stabilizing agent in the prescription of YINHUANG KOUFUYE, improved the dissolubility of compositions such as baicalin, baicalin, successfully solved quality problems such as influencing the oral liquid clarity; In the prescription of YINHUANG KOUFUYE, add the PH stabilizing agent, stablized the pH value of medicinal liquid, successfully solved because of the storage period pH value reduces and made composition hydrolysis such as chlorogenic acid, baicalin, influence the pharmaceutical effectiveness problem.
Drug quality of the present invention is more stable, and drug effect is higher, better efficacy.For showing stability of drug of the present invention, good effect, we have done a large amount of experimentatioies, below experimental example be used to further specify the present invention.
Medicine stability of the present invention is investigated:
Purpose: observe the variation of preparation of the present invention and conventional YINHUANG KOUFUYE at the storage period pH value.
1.1 materials and methods
1.1.1 instrument: 7520 type visible ultraviolet spectrophotometers (Shanghai spectroscopic instruments factory); P2A5 type hydrostatic balance (the Shanghai second balance factory); PHS 25 type acidometers (Shanghai thunder magnetic instrument plant), small beaker, tweezers etc.
1.1.2 medicine: the chamber that keeps sample, our factory provides YINHUANG KOUFUYE: lot number 030,422 1,030,422 3,031,007 1,031,007 2 oral liquids of the present invention: lot number 030,422 1,030,422 3,031,007 1,031,007 2
1.1.3 method: method adopts the natural reserved observational method, carries out character observation and clarity inspection at quarterly intervals respectively; Carried out PH, content inspection respectively every 6 months; Investigate 3 years continuously.Wherein PH is by " 2000 editions one appendix VII G of Chinese pharmacopoeia method is carried out, and assay is according to " carrying out under one one 580 pages YINHUANG KOUFUYE assay items of Chinese pharmacopoeia version in 2000.
1.2 experimental result
1.2.1PH the pH-value determination pH result of the test sees Table 1, table 2.
Table 1 YINHUANG KOUFUYE different standing time of pH mensuration (x ± SD)
| Lot number | 1d | 6 months | 12 months | 18 months | 24 months | 30 months | 36 months |
| 030422 1 030422 3 031007 1 031007 2 | 6.4 6.2 6.3 6.1 | 6.3 6.2 6.1 6.1 | 6.3 6.1 6.0 6.0 | 6.1 6.1 6.0 5.9 | 6.0 6.0 5.8 5.9 | 5.9 5.8 5.7 5.7 | 5.7 5.6 5.4 5.6 |
Table 2 oral liquid of the present invention different standing time of pH measures
| Lot number | 1d | 6 months | 12 months | 18 months | 24 months | 30 months | 36 months |
| 030422 1 030422 3 031007 1 031007 2 | 7.1 7.2 6.9 7.0 | 7.0 7.2 6.9 7.0 | 7.0 7.2 6.8 7.0 | 6.9 7.1 6.8 6.9 | 6.8 7.0 6.7 6.8 | 6.8 7.0 6.7 6.8 | 6.8 6.9 6.7 6.7 |
By table 1, table 2 as seen, YINHUANG KOUFUYE changes greatly at the storage period pH value, and pH value changes more seriously during autoclaving, changes to about 6.2 by original about 7.2, and pH value reduces about 1.0; Preparation of the present invention changes little at the storage period pH value, it is less to the more important thing is that its pH value when autoclaving changes, and obviously there is significant difference in two groups of data, need not do the t check.
1.2.2 the assay result of the test sees Table 3, table 4.
Table 3 different standing time of sample chlorogenic acid contents is measured
| Sample | Lot number | 1d | 6 months | 12 months | 18 months | 24 months | 30 months | 36 months |
| Original oral liquid | 030422 1 030422 3 031007 1 031007 2 030422 1 | 11.92 11.52 11.96 11.69 11.80 | 11.81 11.48 11.80 11.52 11.72 | 11.70 11.38 11.60 11.46 11.54 | 11.63 11.30 11.45 11.30 11.38 | 11.54 11.24 11.29 11.18 11.20 | 11.45 11.00 11.23 11.06 11.06 | 11.23 10.82 11.18 10.85 10.92 |
| Preparation of the present invention | 030422 1 030422 3 031007 1 031007 2 030422 1 030422 1 | 11.84 11.67 11.88 11.89 11.74 11.90 | 11.84 11.67 11.86 11.88 11.74 11.88 | 11.82 11.65 11.86 11.86 11.73 11.87 | 11.80 11.66 11.85 11.86 11.72 11.85 | 11.82 11.65 11.84 11.86 11.72 11.85 | 11.81 11.64 11.80 11.82 11.68 11.83 | 11.78 11.63 11.79 11.80 11.67 11.83 |
As shown in Table 3, YINHUANG KOUFUYE changes greatly at the storage period chlorogenic acid, and chlorogenic acid content reduces near the quality standard value in the time of 36 months, and effect duration can only be 3 years.Preparation of the present invention changes little at the storage period chlorogenic acid content, the effect duration that shows preparation of the present invention is more than triennial.
Table 4 different standing time of sample content of baicalin is measured
| Sample | Lot number | 1d | 6 months | 12 months | 18 months | 24 months | 30 months | 36 months |
| Original oral liquid | 030422 1 030422 3 031007 1 031007 2 030422 1 | 23.00 22.67 22.89 22.77 23.38 | 22.95 22.62 22.77 22.68 23.30 | 22.94 22.54 22.66 22.65 22.27 | 22.90 22.46 22.56 22.58 22.26 | 22.88 22.38 22.50 22.50 22.27 | 22.84 22.30 22.46 22.46 22.15 | 22.73 22.28 22.39 22.40 22.10 |
| Preparation of the present invention | 030422 1 030422 3 031007 1 031007 2 030422 1 030422 1 | 22.81 22.86 23.03 22.96 22.85 22.87 | 22.80 22.83 22.94 22.89 22.85 22.88 | 22.80 22.84 22.92 22.88 22.85 22.87 | 22.78 22.82 22.90 22.85 22.83 22.85 | 22.77 22.82 22.88 22.87 22.83 22.85 | 22.76 22.80 22.87 22.85 22.80 22.84 | 22.76 22.79 22.86 22.85 22.78 22.82 |
By table 3, table 4 as can be known, YINHUANG KOUFUYE changes greatly at the storage period chlorogenic acid, and chlorogenic acid content reduces near the quality standard value in the time of 36 months, and effect duration can only be 3 years.Preparation of the present invention changes little at the storage period chlorogenic acid content; Baicalin changes in two kinds of preparations all not quite can both be significantly higher than the quality standard value, but the stability in preparation of the present invention is better than former preparation, and content of baicalin reduces value and is significantly less than former preparation, shows that baicalin stability in preparation of the present invention strengthens.
In sum, preparation active constituent content height of the present invention, good stability, effect duration is long.
The investigation of curative effect of medication of the present invention:
Except that containing baicalin, also contain compositions such as wogonoside, baicalin, wogonin in the Radix Scutellariae, skullcapflavone all has inhibitory action to Cavia porcellus passive cutaneous anaphylaxis, PCA and rat small intestine in vitro, trachea to the anaphylaxis contractile response due to the antigen, can suppress mastocyte and discharge histamine, the activity that can also suppress cyclo-oxygenase and lipoxygenase, synthesizing of blocking-up prostaglandin and leukotriene, thus bring into play antiinflammatory, anti-allergic effects; Compositions such as baicalin play a part very important to the performance of the drug effect of Radix Scutellariae total flavones, be widely used in sick clinical treatment such as infectious hepatitis, nephritis, pyelonephritis as baicalin, but because baicalins etc. are water-soluble hardly, former preparation can only be worked as impurity and removed, and has influenced the curative effect of product.
For showing medicine of the present invention to the Treatment of Upper Respiratory Tract Infection effect, we have done a large amount of experimentatioies, below experimental example be used to further specify the present invention.
Clinical research: in October, 1999～2004 year May, we entrust the Linyi City hospital of traditional Chinese hospital, Shandong Province to adopt the present invention to treat upper respiratory tract infection 86 examples, and satisfactory effect now is reported as follows.
Clinical data: experimental group 120 examples are all outpatient service acute upper respiratory tract infection patient, all meet following diagnostic criteria: symptom: heating, snivel, nasal obstruction, pharyngalgia, part patient's cough, the course of disease＜48h.
Sign: pharyngeal hyperemia, antiadoncus, but do not have purulent secretion.The laboratory is checked: the WBC counting is normal or on the low side, neutrophil cell≤70%.
Be divided into two groups at random by the prescription on individual diagnosis order: the treatment group: 86 examples.Wherein male 51 examples, women 35 examples; 12～78 years old age, average 45 years old.YINHUANG KOUFUYE group: 34 examples.Wherein male 18 examples, women 16 examples; 12～74 years old age, average 43 years old.Two groups of patient ages, sex, symptom, the course of disease, sign, lab testings are checked through x2, there was no significant difference (P＞0.05).
Therapeutic Method: the treatment group adopts preparation of the present invention; YINHUANG KOUFUYE treatment group is provided by Shandong southern Shandong pharmaceutical factory with YINHUANG KOUFUYE.Two groups of treatments were a course of treatment with 3 days all.Without other drug, surpass 39 ℃ during the treatment, give Physical temperature-lowering as body temperature.Pus tears, purulent sputum person appear in therapeutic process, all as invalid.
Criterion of therapeutical effect:
Produce effects: 24 hours endosome temperature drops of medication are to normal, and upper respiratory tract infection symptoms disappears or obviously alleviates.
Effectively: 72 hours endosome temperature drops are to normal after the medication, and upper airway symptoms, sign obviously alleviate or disappear.Invalid: medication after 72 hours body temperature can not reduce to normally, upper respiratory tract infection symptoms, sign do not alleviate, or pus tears, purulent sputum person occur in 72 hours.
The result: treatment is organized in 86 examples, and produce effects 49 examples account for 57%; Effective 28 examples account for 32.6%, total effective rate 89.6%; Invalid 9 examples account for 10.4%; (purulent sputum 2 examples, 2.32%).In YINHUANG KOUFUYE group 34 examples, produce effects 17 examples account for 50%; Effective 8 examples account for 23.5%, total effective rate 73.5%; Invalid 9 examples account for 26.5%; (pus tears, purulent sputum 3 examples account for 8.8%).Relatively there were significant differences (P＜0.05) for preparation group total effective rate of the present invention and YINHUANG KOUFUYE treatment group.Judge secondary infection with the routine number that occurs pus tears, purulent sputum in the course of treatment, preparation group 2 examples of the present invention (2.32%), YINHUANG KOUFUYE group 3 examples (8.8%).Show that preparation of the present invention obviously is better than the YINHUANG KOUFUYE group to acute upper respiratory tract viral infection curative effect.
Following embodiment is further openly the present invention, need to prove that these embodiment only for optimal way of the present invention, do not limit the scope of protection of present invention.
Embodiment 1
Flos Lonicerae extract (in chlorogenic acid) 6g
Radix Scutellariae extract (in baicalin) 48g
Pluronic F-68 72g
Sodium citrate 1g
Purified water (adding to) 1000ml
Extracting honeysuckle extract, Radix Scutellariae extract are dissolved in water respectively, and Radix Scutellariae extract is regulated pH value to 8 at the sodium hydroxide solution with 8%, filter with Flos Lonicerae extract solution to merge, regulate pH value to 7.2 with 8% sodium hydroxide solution, boiled 1 hour, filter, add pluronic F-68, stir, dissolving, it is an amount of to add simple syrup, adds water to nearly full dose, stirs evenly, add sodium citrate, add water to 1000ml, filter, embedding, sterilization, promptly.
Embodiment 2
Flos Lonicerae extract (in chlorogenic acid) 24g
Radix Scutellariae extract (in baicalin) 12g
Pluronic F-68 72g
Sodium citrate 1g
Purified water (adding to) 1000ml
Extracting honeysuckle extract, Radix Scutellariae extract are dissolved in water respectively, and Radix Scutellariae extract is regulated pH value to 8 at the sodium hydroxide solution with 8%, filter with Flos Lonicerae extract solution to merge, regulate pH value to 7.2 with 8% sodium hydroxide solution, boiled 1 hour, filter, add pluronic F-68, stir, dissolving, it is an amount of to add simple syrup, adds water to nearly full dose, stirs evenly, add sodium citrate, add water to 1000ml, filter, embedding, sterilization, promptly.
Embodiment 3
Flos Lonicerae extract (in chlorogenic acid) 24g
Radix Scutellariae extract (in baicalin) 48g
Pluronic F-68 18g
Sodium citrate 1g
Purified water (adding to) 1000ml
Extracting honeysuckle extract, Radix Scutellariae extract are dissolved in water respectively, and Radix Scutellariae extract is regulated pH value to 8 at the sodium hydroxide solution with 8%, filter with Flos Lonicerae extract solution to merge, regulate pH value to 7.2 with 8% sodium hydroxide solution, boiled 1 hour, filter, add pluronic F-68, stir, dissolving, it is an amount of to add simple syrup, adds water to nearly full dose, stirs evenly, add sodium citrate, add water to 1000ml, filter, embedding, sterilization, promptly.
Embodiment 4
Flos Lonicerae extract (in chlorogenic acid) 24g
Radix Scutellariae extract (in baicalin) 48g
Pluronic F-68 72g
Sodium citrate 0.1g
Purified water (adding to) 1000ml
Extracting honeysuckle extract, Radix Scutellariae extract are dissolved in water respectively, and Radix Scutellariae extract is regulated pH value to 8 at the sodium hydroxide solution with 8%, filter with Flos Lonicerae extract solution to merge, regulate pH value to 7.2 with 8% sodium hydroxide solution, boiled 1 hour, filter, add pluronic F-68, stir, dissolving, it is an amount of to add simple syrup, adds water to nearly full dose, stirs evenly, add sodium citrate, add water to 1000ml, filter, embedding, sterilization, promptly.
Embodiment 5
Flos Lonicerae extract (in chlorogenic acid) 12g
Radix Scutellariae extract (in baicalin) 24g
β-CD 72g
Citric acid 0.1g
Purified water (adding to) 1000ml
Extracting honeysuckle extract, Radix Scutellariae extract are dissolved in water respectively, and Radix Scutellariae extract is regulated pH value to 8 at the sodium hydroxide solution with 8%, filter with Flos Lonicerae extract solution to merge, regulate pH value to 7.2 with 8% sodium hydroxide solution, boiled 1 hour, filter, add β-CD, stir, dissolving, it is an amount of to add simple syrup, adds water to nearly full dose, stirs evenly, add citric acid, add water to 1000ml, filter, embedding, sterilization, promptly.
Embodiment 6
Flos Lonicerae extract (in chlorogenic acid) 12g
Radix Scutellariae extract (in baicalin) 24g
β-CD 18g
Citric acid 1g
Purified water (adding to) 1000ml
Extracting honeysuckle extract, Radix Scutellariae extract are dissolved in water respectively, and Radix Scutellariae extract is regulated pH value to 8 at the sodium hydroxide solution with 8%, filter with Flos Lonicerae extract solution to merge, regulate pH value to 7.2 with 8% sodium hydroxide solution, boiled 1 hour, filter, add β-CD, stir, dissolving, it is an amount of to add simple syrup, adds water to nearly full dose, stirs evenly, add citric acid, add water to 1000ml, filter, embedding, sterilization, promptly.
Embodiment 7
Flos Lonicerae extract (in chlorogenic acid) 12g
Radix Scutellariae extract (in baicalin) 24g
HP-β-CD 38g
Sodium dihydrogen phosphate 1g
Purified water (adding to) 1000ml
Extracting honeysuckle extract, Radix Scutellariae extract are dissolved in water respectively, and Radix Scutellariae extract is regulated pH value to 8 at the sodium hydroxide solution with 8%, filter with Flos Lonicerae extract solution to merge, regulate pH value to 7.2 with 8% sodium hydroxide solution, boiled 1 hour, filter, add HP-β-CD, stir, dissolving, it is an amount of to add simple syrup, adds water to nearly full dose, stirs evenly, add sodium dihydrogen phosphate, add water to 1000ml, filter, embedding, sterilization, promptly.
Embodiment 8
Flos Lonicerae extract (in chlorogenic acid) 12g
Radix Scutellariae extract (in baicalin) 24g
HP-β-CD 24g
Sodium hydrogen phosphate 0.5g
Purified water (adding to) 1000ml
Extracting honeysuckle extract, Radix Scutellariae extract are dissolved in water respectively, and Radix Scutellariae extract is regulated pH value to 8 at the sodium hydroxide solution with 8%, filter with Flos Lonicerae extract solution to merge, regulate pH value to 7.2 with 8% sodium hydroxide solution, boiled 1 hour, filter, add HP-β-CD, stir, dissolving, it is an amount of to add simple syrup, adds water to nearly full dose, stirs evenly, add sodium hydrogen phosphate, add water to 1000ml, filter, embedding, sterilization, promptly.
Embodiment 9
Flos Lonicerae extract (in chlorogenic acid) 12g
Radix Scutellariae extract (in baicalin) 24g
Glucose 30g
Dipotassium hydrogen phosphate 0.5g
Purified water (adding to) 1000ml
Extracting honeysuckle extract, Radix Scutellariae extract are dissolved in water respectively, and Radix Scutellariae extract is regulated pH value to 8 at the sodium hydroxide solution with 8%, filter with Flos Lonicerae extract solution to merge, regulate pH value to 7.2 with 8% sodium hydroxide solution, boiled 1 hour, filter, add glucose, stir, dissolving, it is an amount of to add simple syrup, adds water to nearly full dose, stirs evenly, add dipotassium hydrogen phosphate, add water to 1000ml, filter, embedding, sterilization, promptly.
Embodiment 10
Flos Lonicerae extract (in chlorogenic acid) 12g
Radix Scutellariae extract (in baicalin) 24g
PVP 38g
Diammonium phosphate 0.1g
Purified water (adding to) 1000ml
Extracting honeysuckle extract, Radix Scutellariae extract are dissolved in water respectively, and Radix Scutellariae extract is regulated pH value to 8 at the sodium hydroxide solution with 8%, filter with Flos Lonicerae extract solution to merge, regulate pH value to 7.2 with 8% sodium hydroxide solution, boiled 1 hour, filter, add PVP, stir, dissolving, it is an amount of to add simple syrup, adds water to nearly full dose, stirs evenly, add diammonium phosphate, add water to 1000ml, filter, embedding, sterilization, promptly.
Embodiment 11
Flos Lonicerae extract (in chlorogenic acid) 12g
Radix Scutellariae extract (in baicalin) 24g
PVP 24g
Calcium hydrogen phosphate 0.5g
Purified water (adding to) 1000ml
Extracting honeysuckle extract, Radix Scutellariae extract are dissolved in water respectively, and Radix Scutellariae extract is regulated pH value to 8 at the sodium hydroxide solution with 8%, filter with Flos Lonicerae extract solution to merge, regulate pH value to 7.2 with 8% sodium hydroxide solution, boiled 1 hour, filter, add PVP, stir, dissolving, it is an amount of to add simple syrup, adds water to nearly full dose, stirs evenly, add calcium hydrogen phosphate, add water to 1000ml, filter, embedding, sterilization, promptly.
Claims (8)
1, a kind of YINHUANG KOUFUYE is characterized in that consisting of: transfer PH to 7-8 in the Flos Lonicerae extract 6-24mg/ml of chlorogenic acid, Radix Scutellariae extract 12-48mg/ml, stabilizing agent 18-72mg/ml in baicalin, PH stabilizing agent 0.1-1mg/ml, sodium hydroxide; Wherein said oral liquid solvent is a water, and described stabilizing agent is pluronic F-68, β-CD, glucose or PVP, and described PH stabilizing agent is sodium citrate, citric acid, phosphate or sulfate.
2, oral liquid as claimed in claim 1 is characterized in that: described Flos Lonicerae extract concentration in chlorogenic acid is 12mg/ml, in the Radix Scutellariae extract 24mg/ml of baicalin.
3, oral liquid as claimed in claim 1 is characterized in that described stabilizing agent is HP-β-CD.
4, oral liquid as claimed in claim 3, the concentration that it is characterized in that HP-β-CD is 24-38mg/ml.
5, oral liquid as claimed in claim 1 is characterised in that: described PH stabilizing agent is a sodium citrate.
6, oral liquid as claimed in claim 5 is characterised in that: the concentration of described sodium citrate is 0.1mg/ml-0.5mg/ml.
7,, it is characterized in that described oral liquid preparation technology is as claim 1,2,3,4,5 or 6 described oral liquids:
It is 6-24mg/ml that the extracting honeysuckle extract makes its concentration in chlorogenic acid in finished product in right amount, it is that 12-48mg/ml is dissolved in water respectively that Radix Scutellariae extract makes its concentration in baicalin in finished product in right amount, Radix Scutellariae extract is regulated pH value to 8 at the sodium hydroxide solution with 8%, filter with Flos Lonicerae extract solution and merge, regulate pH value to 7.2 with 8% sodium hydroxide solution, boiled 1 hour, filter, it is 18-72mg/ml that the adding stabilizing agent makes its concentration in finished product, stirs dissolving, it is an amount of to add simple syrup, add water to nearly full dose, stir evenly, add an amount of PH stabilizing agent, the concentration that makes the PH stabilizing agent is 0.1mg/ml-1mg/ml, add water to 1000ml, filter embedding, sterilization, promptly.
8,, it is characterized in that described oral liquid preparation technology is as claim 1,2,3,4,5 or 6 described oral liquids:
It is 12mg/ml that the extracting honeysuckle extract makes its concentration in chlorogenic acid in finished product in right amount, it is that 24mg/ml is dissolved in water respectively that Radix Scutellariae extract makes its concentration in baicalin in finished product in right amount, Radix Scutellariae extract is regulated pH value to 8 at the sodium hydroxide solution with 8%, filter with Flos Lonicerae extract solution and merge, regulate pH value to 7.2 with 8% sodium hydroxide solution, boiled 1 hour, filter, it is 24-38mg/ml that adding stabilizing agent HP-β-CD makes its concentration in finished product, stirs dissolving, it is an amount of to add simple syrup, add water to nearly full dose, stir evenly, add an amount of sodium citrate, the concentration that makes sodium citrate is 0.1mg/ml-0.5mg/ml, add water to 1000ml, filter embedding, sterilization, promptly.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410080022 CN1299707C (en) | 2004-09-24 | 2004-09-24 | Yinhuang oral liquor and its producing process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410080022 CN1299707C (en) | 2004-09-24 | 2004-09-24 | Yinhuang oral liquor and its producing process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1616050A CN1616050A (en) | 2005-05-18 |
| CN1299707C true CN1299707C (en) | 2007-02-14 |
Family
ID=34765580
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410080022 Active CN1299707C (en) | 2004-09-24 | 2004-09-24 | Yinhuang oral liquor and its producing process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1299707C (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101933971B (en) * | 2010-09-19 | 2012-04-18 | 江西天施康中药股份有限公司 | Oral liquid of honeysuckle flower and baical skullcap root and preparation method thereof |
| FR3128373A1 (en) * | 2021-10-22 | 2023-04-28 | Jr | COMPOSITION FOR ITS USE IN THE CUTANEOUS SYNTHESIS OF HYALURONIC ACID, IN THE IMMUNO-CUTANEOUS RESPONSE AND IMPROVEMENT OF THE SKIN |
-
2004
- 2004-09-24 CN CN 200410080022 patent/CN1299707C/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN1616050A (en) | 2005-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101041009A (en) | Chinese traditional medicine compound for treating faucitis | |
| CN1723955A (en) | Extractive of rhizome belamcandae, prepn. method and use thereof | |
| CN1686185A (en) | Traditional Chinese medicina preparation for treating oral cavity, throat disease and its preparation method | |
| CN1883599A (en) | Chinese medicinal composition for treating women's episioitis or colpitis and method for preparing same | |
| CN1775274A (en) | Cough-relieving sputum-resolving medicinal composition and preparing method | |
| CN1299707C (en) | Yinhuang oral liquor and its producing process | |
| CN101053619A (en) | Medicine for treating pulmonary fibrosis | |
| CN100337658C (en) | Chinese medicine composition for treating cold anemopyretic syndrome, and its preparing method | |
| CN1698691A (en) | Medicine for treating cough due to lung heat/toxin and preparation method thereof | |
| CN1579467A (en) | Anti-virus medicine | |
| CN1634413A (en) | Bastard speedwell injection and preparation method thereof | |
| CN1559420A (en) | Medicne tablets with function of delaying senility, and prepn. method therefor | |
| CN1290570C (en) | Medical liquor for treating bronchial asthma and drug administering apparatus thereof | |
| CN1839920A (en) | Astragaloside injection and preparation method thereof | |
| CN1840008A (en) | Chinese medicinal granule for clearing pharynx and moistening throat and preparation method thereof | |
| CN1640408A (en) | Multifunctional anti virus lozenge | |
| CN1301099C (en) | Earthworm drip pill and its preparation method | |
| CN1593558A (en) | Sarcandra extract and its application | |
| CN1105572C (en) | Compound rhododendron senivainii granule and its preparing method | |
| CN1055022C (en) | Compound interferon antiviral drug, prepn. and use thereof | |
| CN1267116C (en) | Medicine for treating gingivitis and periodontitis and preparation method thereof | |
| CN1435248A (en) | Chinese medicine preparation for treating upper respiratory system diseases, skin infection and pile, and preparing method thereof | |
| CN103705642B (en) | A kind of Chinese medicine for the treatment of tinea unguium | |
| CN1634340A (en) | Medicinal composition for preventing and treating children respiratory system diseases and preparation method thereof | |
| CN1931231A (en) | Chinese medicine gargle for treating periodontal disease and stomatocace |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Lunan Pharmaceutical Co., Ltd. Assignor: Lunan Pharmaceutical Group Co., Ltd. Contract record no.: 2010370000516 Denomination of invention: Yinhuang oral liquor and its producing process Granted publication date: 20070214 License type: Exclusive License Open date: 20050518 Record date: 20100909 |
|
| EC01 | Cancellation of recordation of patent licensing contract |
Assignee: Lunan Pharmaceutical Co., Ltd. Assignor: Lunan Pharmaceutical Group Co., Ltd. Contract record no.: 2010370000516 Date of cancellation: 20131016 |
|
| LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model |